Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medication Repository topic
No spam. Unsubscribe anytime.
Committee considers expanding state support, purchasing authority for medication repository
Summary
Senate File 1785 would provide base funding and limited purchasing authority for Minnesota's medication repository program and clarify disposal authority; testimony highlighted rapid program growth since 2023, safety procedures and the need for ongoing funding to expand a dispensing pharmacy.
Senator John Mann introduced Senate File 17 85 on March 11 as legislation to "build on Minnesota's medication repository program" by providing base funding and a small purchasing mechanism to fill shortfalls, he said. "The big pieces in this bill are that it includes base funding to keep the program up and running, and it starts a purchasing program to fill in the holes," Mann said.
Rachel Rockwell, managing director and pharmacist in charge at Roundtable Rx, told the committee the repository redistributes sealed, unexpired donated medications after licensed-pharmacist inspection and does not accept controlled substances. Rockwell said state funding provided since July 2023 produced a 300% increase in redistributed medications and allowed growth toward opening a dispensing pharmacy to deliver statewide by mail. "Receiving state funding has better aligned our state's program with other states," Rockwell said.
Rockwell described two statutory changes requested by Minnesota Board of Pharmacy staff: an amendment to "Subdivision 6" to permit Roundtable Rx's dispensing pharmacy to purchase medications from a wholesaler when donated stock is insufficient (while prioritizing donated stock), and a clarification to "Subdivision 10" to allow local repositories to destroy donated medication that is damaged in transit or expired. She said the changes mirror practices in Iowa and Wyoming where dispensing pharmacies operate.
Rockwell offered independent impact estimates from a third-party study that Roundtable Rx's reported medication value of about $640,000 understates impact by roughly 60%, estimating $1.8 million in medication value distributed and nearly $2.8 million in broader system value since opening in 2020. She and Senator Mann said the program seeks recurring base funding; committee members discussed whether funding could be scaled and whether policy language changes make sense even without immediate ongoing appropriations. Rockwell confirmed the program would be at risk of dissolution without further funding.
Dr. Rowan Mann, identified as an original founder, and other members of the committee discussed program sustainability, prior one-time funding for fiscal years 2023–24 and the push for base funding. Senator Abeler questioned what would happen if state funding stopped; Rockwell said the program would effectively dissolve.
The committee adopted no appropriation on the floor; Chair Wiklendt laid over Senate File 17 85 for possible inclusion. No formal roll-call vote on the bill was recorded.
